Clinical Scorecard: Expression Levels of DCTN2 and PAX8 in Prostate Cancer Tissues: Correlation with Clinicopathological Characteristics and Prognostic Implications
At a Glance
Category
Detail
Condition
Prostate Cancer
Key Mechanisms
DCTN2 and PAX8 expression levels in cancer tissues
Target Population
Patients with prostate cancer
Care Setting
Clinical oncology and pathology
Key Highlights
DCTN2 and PAX8 expression rates are higher in prostate cancer tissues than adjacent tissues.
Expression levels correlate with tumor differentiation, lymph node metastasis, clinical stage, and Gleason score.
Positive expression of DCTN2 and PAX8 is associated with lower 3-year progression-free survival rates.
Guideline-Based Recommendations
Diagnosis
Immunohistochemical staining for DCTN2 and PAX8 in prostate cancer tissues.
Management
Consideration of DCTN2 and PAX8 expression levels in treatment planning and prognosis assessment.
Monitoring & Follow-up
Regular follow-up for tumor progression, including local recurrence and biochemical recurrence.
Risks
Lymph node metastasis, clinical stage, Gleason score, and DCTN2 and PAX8 expression are risk factors for poor prognosis.
Patient & Prescribing Data
103 patients with prostate cancer admitted between February 2020 and February 2022.
Radical surgery followed by endocrine therapy is the preferred treatment.
Clinical Best Practices
Utilize immunohistochemical analysis for assessing DCTN2 and PAX8 in prostate cancer.
Incorporate expression levels into prognostic evaluations.
